Lacidipin Teva

Lacidipine, the active ingredient in Lacidipin, is a calcium channel blocker presented as a tablet for oral use. It treats hypertension in adults by helping to lower elevated blood pressure. GNH USA supplies Lacidipin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacidipine is a dihydropyridine calcium channel blocker used primarily in the management of high blood pressure.

- Hypertension: lowers elevated blood pressure, reducing the risk of cardiovascular complications.

Lacidipine may cause a range of adverse reactions, some of which are more frequently observed than others.

Common Side Effects: - Headache: mild to moderate pain often occurring after the first dose. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Tachycardia: increased heart rate. - Nausea: mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, itching, or swelling of the face and throat. - Arrhythmia: irregular heart rhythm. - Angioedema: rapid swelling of deeper skin layers, potentially airway‑compromising.

Before initiating Lacidipine therapy, several safety considerations should be reviewed. - Blood pressure monitoring: regularly check to avoid excessive lowering. - Hepatic function: assess liver enzymes in patients with liver disease. - Elderly patients: start at lower doses and monitor for orthostatic hypotension. - Concomitant antihypertensives: adjust doses to prevent additive effects. - CYP3A4 inhibitors: avoid strong inhibitors that may raise Lacidipine levels. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lacidipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Grapefruit juice: can markedly raise Lacidipine exposure. - Other potent vasodilators: risk of severe hypotension.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: may enhance bradycardia. - Diuretics: can affect electrolyte balance and blood pressure control. - Calcium supplements or antacids: may reduce Lacidipine absorption.